Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign In
  • Home
  • World
    Sections
    • World Home
    • Israel-Hamas war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • Japanese stock index suffers worst day since 1987 as global rout intensifies
    • Labour has the UK’s wealthier over-65s in its sights
    • UK universities regulator plans for looming insolvencies
    • Fresh violence flares after dozens of rioters arrested across England
    • Why global investors find it so easy to sell Japan
  • UK
    Sections
    • UK Home
    • UK Economy
    • UK Politics
    • UK Companies
    • Personal Finance
    Most Read
    • Labour has the UK’s wealthier over-65s in its sights
    • UK universities regulator plans for looming insolvencies
    • Fresh violence flares after dozens of rioters arrested across England
    • Why are the far right rioting in England?
    • Why pension funds should not be patriots
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Blessed are the bean counters — except when it comes to growth
    • Widespread boycotts in Muslim countries hammer western brands
    • Novo Nordisk boosts research as rivals challenge weight-loss leader
    • Why pension funds should not be patriots
    • Woodside to buy OCI Global’s ‘blue’ ammonia project for $2.3bn
  • Tech
    Sections
    • Tech Home
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
    Most Read
    • Lloyds hires Amazon Web Services executive as its new AI chief
    • A rollercoaster earnings season for tech stocks
    • Elliott says Nvidia is in a ‘bubble’ and AI is ‘overhyped’
    • Brain implant made from graphene is set to begin UK clinical trial
    • Big Tech groups say their $100bn AI spending spree is just beginning
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • Japanese stock index suffers worst day since 1987 as global rout intensifies
    • Why global investors find it so easy to sell Japan
    • Asset managers fret over lost gains as investor cash piles up on sidelines
    • Everyone calm down
    • Woodside to buy OCI Global’s ‘blue’ ammonia project for $2.3bn
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Why global investors find it so easy to sell Japan
    • The power of choosing your words wisely
    • Blessed are the bean counters — except when it comes to growth
    • The volatile far right on UK streets is becoming more difficult to label
    • Why pension funds should not be patriots
  • Lex
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • Cities on screen: Choose Edinburgh
    • Tesla attempt to save Elon Musk’s $56bn pay package gets sceptical reception
    • ‘Gone are the days of taking a phone call in the open’: why office pods are everywhere
    • Bolt promises benefits to gig workers ahead of court battle with union
    • How Roger Federer rode the ‘beautiful wave’ of tennis for 24 years
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • What and how to read
    • Cities on screen: Choose Edinburgh
    • One of Scandinavia’s buzziest fashion brands is ready to scale
    • Photobombing de Gaulle: how a forgotten picture rewrites the history of WWII
    • Could music win it for Kamala Harris?
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Lex
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Roche Holding AG

  • Monday, 29 July, 2024
    Roche to fast-track weight-loss pill to compete with rivals

    Swiss drugmaker unveils promising data for obesity drug

    Passers-by are silhouetted as they walk along the banks of river Rhine next to the Roche towers
  • Thursday, 16 May, 2024
    Roche says obesity drug results ‘encouraging’ as competition heats up

    Weekly injection delivered 18.8% weight loss over 24 weeks

    A scientist works inside Roche’s research lab
  • Wednesday, 24 April, 2024
    Roche cuts drug pipeline in effort to revitalise business

    Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’

  • Friday, 23 February, 2024
    European equities
    Europe’s ‘Granolas’ fuel record stock market surge

    Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’

    A montage showing a Wegovy injection dose, the ASML logo and luxury products, including nail polish and a handbag, against two chart lines
  • Wednesday, 3 January, 2024
    Antibiotic resistance
    New drug offers hope in fight against hospital ‘superbugs’

    Potential remedy targets leading antibiotic-resistant pathogen that causes life-threatening infections in patients

    A computer illustration of multi-drug resistant Acinetobacter baumannii bacteria inside biofilm
  • Monday, 4 December, 2023
    Lex
    Roche: fat fighter drugs buy must precede trial wins Premium content

    The Swiss pharma group needs to settle investor jitters with its latest acquisition

    Photograph of Thomas Schinecker.Carmot Therapeutics is the second bolt-on acquisition by Roche’s new chief executive Thomas Schinecker in less than two months
  • Monday, 4 December, 2023
    Roche to buy Carmot for up to $3.1bn as race for obesity drugs intensifies

    Swiss pharmaceutical group is under pressure to strengthen its pipeline of medicines

    The Roche sign on at the company’s headquarters in Basel
  • Monday, 23 October, 2023
    Lex
    Roche: Telavant acquisition fails to inflame investors’ spirits Premium content

    Bolt-on acquisitions, however interesting, will not get Swiss pharmaceuticals group Roche out of its funk

    Roche chief executive Thomas Schinecker
  • Monday, 23 October, 2023
    Drugs research
    Roche agrees $7.1bn deal for Telavant to boost drug pipeline

    Swiss pharma group acquires rights to develop and manufacture bowel disease treatment

    A Roche sign on the side of the company’s headquarters in Basel, Switzerland
  • Wednesday, 23 August, 2023
    Drugs research
    Roche inadvertently publishes positive results from lung cancer drug study

    Shares in Swiss pharma group rally after analyst discovers data on immunotherapy medicine on website

    The Roche logo on its headquarters in Basel, Switzerland
  • Tuesday, 22 August, 2023
    Pharmaceuticals sector
    Use of horseshoe crabs’ blue blood puts pharma groups under scrutiny

    BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances

    Person holds a horseshoe crab
  • Monday, 14 November, 2022
    Roche late-stage Alzheimer’s trials end in failure

    Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

    A brain scan showing Alzheimer’s disease
  • Tuesday, 18 October, 2022
    Roche’s sales of Covid drugs fall by $1bn

    Swiss pharma group says demand for coronavirus tests dropped as severity of virus ebbed

    Roche chief executive Severin Schwan
  • Thursday, 21 July, 2022
    Roche’s chief executive to step down and become chair

    Severin Schwan will be succeeded by Thomas Schinecker, head of drugmaker’s diagnostics unit

    Severin Schwan has helmed Roche as chief executive since 2008
  • Monday, 25 April, 2022
    LexCoronavirus treatment
    Roche/diagnostics: Covid vaccine victory means test makers take a rest Premium content

    Do not dismiss the possibility of another upturn in the coronavirus testing market

    A man gets tested for Covid in New York City
  • Monday, 25 April, 2022
    Roche sales boosted by North American demand for Covid tests

    Swiss pharmaceuticals group expects revenue from coronavirus treatments will decline this year

    A Roche rapid test for coronavirus
  • Wednesday, 6 April, 2022
    LexPharmaceuticals sector
    Breast cancer: precision drugs make inroads against stubborn tumours Premium content

    New therapies replace a blunderbuss with a stiletto

    A phial and packs of Herceptin sit on a pharmacy shelf
  • Thursday, 4 November, 2021
    Novartis to sell its Roche stake worth $21bn

    Twenty-year shareholding had kept the two Swiss drugmakers closely linked

    Roche logo
  • Thursday, 5 August, 2021
    Due Diligence
    SoftBank’s newfangled bet on a 125-year-old drugmaker Premium content

    Plus, inside the cut-throat game of private equity and European football

  • Wednesday, 4 August, 2021
    LexPharmaceuticals sector
    SoftBank/Roche: Northstar reorients to embrace drug development Premium content

    The Swiss company and Japanese tech investor both have a taste for big data and disruption

    Roche HQ in Basel, Switzerland
  • Wednesday, 4 August, 2021
    SoftBank Group Corp
    SoftBank acquires $5bn stake in Swiss drugmaker Roche

    Deal struck through unit of Japanese technology group that was behind ‘Nasdaq whale’ trade

    A Roche plant in the Swiss village of Rotkreuz
  • Monday, 5 July, 2021
    News in-depthPharmaceuticals sector
    Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

    Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

  • Thursday, 13 May, 2021
    Covid-19 vaccines
    Roche chief compares waiving vaccine patents to East German nationalisation

    Severin Schwan believes proposal is ‘counterproductive’ and will not solve supply shortages

    Severin Schwan
  • Wednesday, 21 April, 2021
    Covid-19 test demand boosts Roche

    Swiss pharmaceutical company reports 55% jump in diagnostic sales

    A Roche Covid-19 self-test
  • Friday, 2 April, 2021
    LexPharmaceuticals sector
    Roche/Novartis: rivals play king of the pill Premium content

    The pharmaceuticals are battling in similar markets, but their share price performances have diverged

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2024. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Edition:UK
International
Subscribe for full access

Top sections

  • Home
  • World
    • Israel-Hamas war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • UK
    • UK Economy
    • UK Politics
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Lex
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Alphaville
  • FT Edit
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In